RxDoctor Payments Data

Lyudmila Carter, MD

Internal Medicine · Hinesville, GANPI 1285071340

Payments from drug & device makers

$1,743in general payments, 2019–2025

Across 89 payments — averaging $19.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$310
  • AbbVie$303
  • Indivior Inc.$268
  • Pfizer$182
  • Merck$169
  • AstraZeneca$96
  • plus $416 from 12 others

What the payments were for

  • Food & beverage$1,71498%
  • Education$302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,743 in reported general payments places this provider in the 70th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$43,611
Medicare patients
121
Services billed
697

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide91$105,575
EliquisApixaban61$89,536
FarxigaDapagliflozin Propanediol71$86,424
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$54,602
Breztri AerosphereBudesonide/Glycopyr/Formoterol55$49,237
JanuviaSitagliptin Phosphate40$39,507
MounjaroTirzepatide29$39,160
TrulicityDulaglutide34$37,267
JardianceEmpagliflozin24$37,025
RybelsusSemaglutide20$31,772
Nurtec OdtRimegepant Sulfate13$15,189
Repatha SureclickEvolocumab16$13,279
Breo ElliptaFluticasone/Vilanterol15$8,718
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$6,042
Combivent RespimatIpratropium/Albuterol Sulfate12$5,810

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$310$137,347111 claims
AstraZenecaFarxiga, Breztri Aerosphere$96$135,661126 claims
PfizerEliquis, Nurtec Odt$182$104,72574 claims
Lilly USA, LLCMounjaro, Trulicity$49$76,42763 claims
Boehringer IngelheimJardiance, Combivent Respimat$16$42,83536 claims
MerckJanuvia$169$39,50740 claims
AbbVieSynthroid$303$1,41629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Hinesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →